We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.9B
1-Year Est. Return 121.13%
This Fund
S&P 500
This Quarter Est. Return
+1.21%
1 Year Est. Return
+121.13%
3 Year Est. Return
+281.43%
5 Year Est. Return
+350.91%
10 Year Est. Return
AUM
$1.9B
AUM Growth
-$88M
Cap. Flow
+$2.36M
Cap. Flow %
0.12%
Top 10 Hldgs %
47.92%
Holding
151
New
44
Increased
37
Reduced
36
Closed
31

Top Sells

Rank Stock Value
1
GSK icon
GSK
GSK
+$48.5M
2
DHR icon
Danaher
DHR
+$42.6M
3
VERA icon
Vera Therapeutics
VERA
+$38.7M
4
VRDN icon
Viridian Therapeutics
VRDN
+$31.7M
5
BRKR icon
Bruker
BRKR
+$27.9M

Sector Composition

Rank Sector Weight
1 Healthcare 74.35%
2 Real Estate 5.59%
3 Financials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
CBLL
151
CeriBell Inc
CBLL
$642M
-17,094
Closed -$375K

Similar funds

Eversept Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Eversept Partners held 151 positions worth $1.9B, down 4.4% from $1.98B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Eversept Partners's Q1 2026 filing shows 44 new, 37 increased, 36 reduced and 31 closed positions. Its largest new stake was Welltower: 180,953 shares worth $35.8M. The largest sale was GSK, an estimated $48.5M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 90% a quarter earlier, followed by Real Estate and Financials.

  • Eversept Partners's largest Q1 2026 buy was Welltower: 180,953 shares worth $35.8M.
  • Eversept Partners added most to Brookdale Senior Living in Q1 2026, an estimated $44.7M increase.
  • Eversept Partners's biggest Q1 2026 reduction was GSK, cutting an estimated $48.5M.
  • Eversept Partners fully exited Danaher in Q1 2026, selling an estimated $42.6M.
  • Eversept Partners's ten largest holdings make up 48% of its $1.9B portfolio in Q1 2026.
  • Eversept Partners opened 44 new positions and closed 31 in Q1 2026.
  • Eversept Partners's portfolio value fell 4.4% quarter-over-quarter to $1.9B.

Based on Eversept Partners's 13F filing for Q1 2026, filed 15 May 2026.